IVA — Inventiva S.A. Stock Price, Chart & AI Report

Neutral Jun 2, 2026 • 05:30 UTC GlobeNewswire Inc. • Na

Inventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris

Inventiva, a clinical-stage biopharmaceutical company developing oral therapies for MASH treatment, announced a temporary trading halt on Euronext Paris on June 2, 2026, ahead of a proposed financing transaction. Trading was expected to resume at approximately 3:30 p.m. CEST, coinciding with the opening of Nasdaq trading. The company reported Q1 2026 cash and equivalents of €75.0 million plus €121.5 million in short-term deposits.

IVA trading halt financing transaction MASH treatment lanifibranor NATiV3 Phase 3 trial biopharmaceutical Euronext Paris

Sentiment note

The announcement of a financing transaction is typically positive for a clinical-stage biotech company, indicating investor confidence and funding to advance development. However, the sentiment is tempered to neutral due to lack of specific details about the financing terms, amount, or strategic implications. The company maintains a solid cash position (€196.5 million combined), which is neither alarming nor exceptional for a clinical-stage firm.

Neutral Jun 2, 2026 • 05:30 UTC GlobeNewswire Inc. • Na

Inventiva annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris

Inventiva announced on June 2, 2026, that trading of its ordinary shares on Euronext Paris will be temporarily suspended starting at market open (9:00 CEST) pending disclosure of a financing operation. Trading is expected to resume later that day around 15:30 CEST, coinciding with potential trading resumption on Nasdaq. The company is a clinical-stage biopharmaceutical firm developing lanifibranor, a pan-PPAR agonist, for treating MASH (metabolic dysfunction-associated steatohepatitis).

IVA trading suspension financing operation Euronext Paris Nasdaq lanifibranor MASH treatment clinical-stage biopharmaceutical

Sentiment note

The announcement of a trading suspension ahead of a financing operation is procedurally neutral. While financing typically indicates capital needs, the suspension itself is a standard regulatory procedure. Without details on the financing terms or impact, sentiment remains neutral pending further disclosure.

Neutral May 26, 2026 • 20:00 UTC GlobeNewswire Inc. • Na

Inventiva Reports 2026 First Quarter Financial Information¹

Inventiva, a clinical-stage biopharmaceutical company, reported Q1 2026 financial results showing cash and cash equivalents of €75.0 million and short-term deposits of €121.5 million, down from €99.3 million and €131.6 million respectively at year-end 2025. The company estimates its current resources will fund operations until mid-Q1 2027, or mid-Q3 2027 if Tranche 3 warrants from its October 2024 structured financing are fully exercised for €116.0 million. The company generated no revenues in Q1 2026 and expects NATiV3 Phase 3 trial topline results in Q4 2026.

IVA MASH treatment lanifibranor Phase 3 clinical trial cash runway structured financing NATiV3 trial pan-PPAR agonist

Sentiment note

The company reported declining cash reserves (down €24.3M quarter-over-quarter) with no revenue generation, indicating ongoing cash burn typical for clinical-stage biotech. However, the company maintains adequate runway until at least Q1 2027 and has potential additional funding through warrant exercises. The upcoming NATiV3 Phase 3 trial results in Q4 2026 represent a key catalyst, but the outcome remains uncertain. The neutral sentiment reflects the balanced view of adequate near-term funding against typical clinical-stage risks and lack of revenue.

Neutral May 26, 2026 • 20:00 UTC GlobeNewswire Inc. • Na

Inventiva publie ses informations financières du premier trimestre 2026¹

Inventiva, a clinical-stage biopharmaceutical company, reported cash and equivalents of €75 million and short-term deposits of €121.5 million as of March 31, 2026. The company estimates its liquidity will fund operations until mid-Q1 2027, or potentially mid-Q3 2027 if warrant exercises from its structured financing reach €116 million. No revenue was recorded in Q1 2026. Key milestone: NATiV3 Phase 3 trial results for lanifibranor (MASH treatment) are expected in Q4 2026.

IVA cash position liquidity runway lanifibranor MASH treatment NATiV3 trial clinical-stage biotech warrant financing

Sentiment note

The company maintains adequate liquidity (€196.5M combined cash and deposits) to fund operations into 2027, but faces typical clinical-stage biotech risks. No revenue generation and dependence on trial outcomes and future financing create uncertainty. The Q1 cash burn (€24.3M decrease) is expected but the company's runway depends on warrant exercises and trial success, which are not guaranteed.

Positive May 21, 2026 • 20:00 UTC GlobeNewswire Inc. • Not Specified

Inventiva to Present at 2026 Jefferies Global Healthcare Conference

Inventiva, a clinical-stage biopharmaceutical company developing oral therapies for MASH treatment, announced that CEO Andrew Obenshain will present at the 2026 Jefferies Global Healthcare Conference on June 3, 2026, in New York City. The company is evaluating lanifibranor, a pan-PPAR agonist, in the NATiV3 Phase 3 clinical trial.

IVA Inventiva biopharmaceutical MASH lanifibranor Phase 3 clinical trial Jefferies Global Healthcare Conference pan-PPAR agonist

Sentiment note

The company is advancing its lead candidate lanifibranor through a pivotal Phase 3 trial (NATiV3) for MASH treatment, strengthening its leadership team ahead of expected data readout, and presenting at a major healthcare conference, all indicating progress toward potential commercialization and investor confidence.

Positive May 21, 2026 • 20:00 UTC GlobeNewswire Inc. • Na

Inventiva présentera lors de la 2026 Jefferies Global Healthcare Conference

Inventiva announced that CEO Andrew Obenshain will present at the 2026 Jefferies Global Healthcare Conference on June 3, 2026 in New York. The biopharmaceutical company is developing lanifibranor, an oral therapy for MASH treatment, currently in Phase 3 clinical trials.

IVA Inventiva Jefferies Global Healthcare Conference lanifibranor MASH Phase 3 clinical trial biopharmaceutical oral therapy

Sentiment note

The company is advancing its lead candidate lanifibranor through Phase 3 clinical trials for MASH treatment and is presenting at a major healthcare conference, indicating progress in development and investor engagement. The mention of strengthening the leadership team ahead of expected Phase 3 data readout suggests confidence in upcoming milestones.

Positive May 13, 2026 • 06:30 UTC GlobeNewswire Inc. • Na

Inventiva présentera plusieurs abstracts lors de l’EASL Congress 2026

Inventiva announced it will present two abstracts at the EASL Congress 2026 in Barcelona (May 27-30) showcasing lanifibranor's improvements in histological parameters and cardiometabolic markers in MASH patients, independent of weight change and associated with adiponectin induction. The company will also exhibit at booth 35.

IVA lanifibranor MASH EASL Congress 2026 clinical trial PPAR agonist hepatic disease metabolic dysfunction

Sentiment note

The company is presenting clinical data on its lead candidate lanifibranor at a major international conference, demonstrating therapeutic efficacy in MASH treatment. The presentation of positive histological and cardiometabolic improvements, combined with FDA Breakthrough Therapy and Fast Track designations, indicates clinical progress and regulatory support for the drug candidate.

Positive May 13, 2026 • 06:30 UTC GlobeNewswire Inc. • Na

Inventiva to Present Abstracts at the EASL Congress 2026

Inventiva announced it will present two abstracts at the EASL Congress 2026 in Barcelona (May 27-30) showcasing lanifibranor's effectiveness in treating metabolic dysfunction-associated steatohepatitis (MASH). The presentations highlight improvements in histological parameters, cardiometabolic markers, and liver sinusoidal endothelial cell changes independent of weight loss. Lanifibranor is a pan-PPAR agonist currently in Phase 3 clinical trials and has received FDA Breakthrough Therapy and Fast Track designations.

IVA lanifibranor MASH treatment EASL Congress 2026 pan-PPAR agonist Phase 3 clinical trial FDA Breakthrough Therapy metabolic dysfunction

Sentiment note

The company is presenting promising clinical data on its lead candidate lanifibranor at a major international conference, demonstrating therapeutic efficacy in MASH treatment. The drug has received FDA Breakthrough Therapy and Fast Track designations, and the company is advancing toward Phase 3 data readout and potential commercialization, indicating strong clinical progress.

Positive Apr 22, 2026 • 20:00 UTC GlobeNewswire Inc. • Na

Inventiva Strengthens Leadership Team Ahead of Expected Phase 3 Data Readout of Lanifibranor

Inventiva announced the recruitment of three new senior executives: Axel-Sven Malkomes as Chief Financial Officer, Susan Coles as Chief Legal Officer, and Pamela Herbster as Chief People Officer. These appointments strengthen the company's leadership team ahead of the anticipated Phase 3 top-line data readout for lanifibranor in Q4 2026. Previous CFO Jean Volatier will transition to EVP Finance & Corporate Social Responsibility.

IVA BNTX leadership appointments Chief Financial Officer Chief Legal Officer Chief People Officer lanifibranor Phase 3 trial

Sentiment note

The company is strengthening its leadership team with experienced executives from prominent biotech firms ahead of a critical Phase 3 data readout. This demonstrates organizational maturation and preparation for potential commercialization, which are positive indicators for company progression and investor confidence.

Positive Apr 22, 2026 • 20:00 UTC GlobeNewswire Inc. • Na

Inventiva renforce son équipe de direction à l’approche des résultats de Phase 3 du lanifibranor

Inventiva announced the appointment of three new executives: Axel-Sven Malkomes as Chief Financial Officer, Susan Coles as General Counsel, and Pamela Herbster as Chief Human Resources Officer. These hires strengthen the company's leadership ahead of expected Phase 3 trial results for lanifibranor in Q4 2026. Previous executives Jean Volatier and Nathalie Harroy transition to new roles within the company.

IVA executive appointments Chief Financial Officer General Counsel Chief Human Resources Officer Phase 3 trial lanifibranor MASH treatment

Sentiment note

The company is strengthening its executive team with experienced industry veterans ahead of a critical Phase 3 trial readout expected in Q4 2026. The appointments demonstrate preparation for potential commercialization and regulatory submissions, indicating confidence in the company's trajectory and upcoming milestones.

Neutral Apr 8, 2026 • 20:00 UTC GlobeNewswire Inc. • Na

Inventiva annonce le dépôt de son Document d’Enregistrement Universel 2025 et de son Rapport Annuel 2025 (« Form 20-F »)

Inventiva, a clinical-stage biopharmaceutical company, has filed its 2025 Universal Registration Document with the AMF and its Form 20-F with the SEC. The company reported €4.5 million in revenues for 2025 and held €99.3 million in cash and €131.6 million in short-term deposits as of December 31, 2025. Inventiva is developing lanifibranor, a pan-PPAR agonist, for the treatment of MASH (metabolic dysfunction-associated steatohepatitis) in its Phase 3 NATiV3 clinical trial.

IVA biopharmaceutical MASH treatment lanifibranor Phase 3 clinical trial financial results cash position

Sentiment note

The article is primarily a regulatory filing announcement with basic financial metrics. While the company maintains a solid cash position (€230.9 million combined) and is progressing with Phase 3 trials, the article lacks forward-looking statements, clinical trial results, or strategic updates that would indicate positive or negative momentum. The tone is factual and informational rather than highlighting achievements or concerns.

Neutral Apr 8, 2026 • 20:00 UTC GlobeNewswire Inc. • Na

Inventiva announces filing of its 2025 Universal Registration Document and 2025 Annual Report on Form 20-F

Inventiva, a clinical-stage biopharmaceutical company, announced the filing of its 2025 Universal Registration Document with the French AMF and its 2025 Annual Report on Form 20-F with the SEC. The company reported 2025 revenues of €4.5 million and cash/short-term deposits totaling €230.9 million as of December 31, 2025. Inventiva continues to evaluate lanifibranor, a pan-PPAR agonist, in the NATiV3 Phase 3 clinical trial for MASH treatment.

IVA biopharmaceutical MASH treatment lanifibranor Phase 3 clinical trial pan-PPAR agonist financial results regulatory filing

Sentiment note

The article is primarily a regulatory filing announcement with standard financial disclosures. While the company maintains a solid cash position (€230.9 million) and is progressing with its Phase 3 trial, the modest revenue (€4.5 million) and routine nature of the filing announcement do not indicate significant positive or negative developments. The tone is factual and informational rather than highlighting breakthrough results or concerning setbacks.